Free Trial

Dyne Therapeutics (DYN) Stock Price, News & Analysis

Dyne Therapeutics logo
$10.37 +0.12 (+1.14%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Dyne Therapeutics Stock (NASDAQ:DYN)

Key Stats

Today's Range
$10.05
$10.36
50-Day Range
$8.18
$14.78
52-Week Range
$6.36
$47.45
Volume
259,387 shs
Average Volume
2.55 million shs
Market Capitalization
$1.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.25
Consensus Rating
Buy

Company Overview

Dyne Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

DYN MarketRank™: 

Dyne Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 467th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dyne Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dyne Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dyne Therapeutics is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dyne Therapeutics is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dyne Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dyne Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.06% of the outstanding shares of Dyne Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently decreased by 3.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    Dyne Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dyne Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.06% of the outstanding shares of Dyne Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently decreased by 3.91%, indicating that investor sentiment is improving.
  • News Sentiment

    Dyne Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for Dyne Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    3 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dyne Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $911,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    14.14% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dyne Therapeutics' insider trading history.
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Equities Analysts Offer Predictions for DYN Q3 Earnings
See More Headlines

DYN Stock Analysis - Frequently Asked Questions

Dyne Therapeutics' stock was trading at $23.56 at the start of the year. Since then, DYN shares have decreased by 56.5% and is now trading at $10.25.

Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its quarterly earnings results on Monday, July, 28th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02.

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Top institutional shareholders of Dyne Therapeutics include Aberdeen Group plc (0.43%), Y Intercept Hong Kong Ltd (0.09%), Mutual of America Capital Management LLC (0.04%) and Teacher Retirement System of Texas (0.01%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, John Cox, Oxana Beskrovnaya, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Richard William Scalzo, Dirk Kersten, Johanna Friedl-Naderer and Carlo Incerti.
View institutional ownership trends
.

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/28/2025
Today
8/05/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DYN
Previous Symbol
NYSE:DYN
CIK
1818794
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$52.00
Low Price Target
$9.00
Potential Upside/Downside
+253.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$317.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.12%
Return on Assets
-56.75%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
16.83
Quick Ratio
16.83

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.19 per share
Price / Book
1.66

Miscellaneous

Outstanding Shares
142,264,000
Free Float
112,716,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
1.08

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:DYN) was last updated on 8/5/2025 by MarketBeat.com Staff
From Our Partners